IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma

Blood

Volumn 109, Issue 7, 2007, Pages 3060-3068

  Ramos, Juan Carlos ^a   Ruiz Jr , Phillip ^a   Ratner, Lee ^b   Reis, Isildinha M ^a   Brites, Carlos ^c   Pedroso, Celia ^c   Byrne Jr , Gerald E ^a   Toomey, Ngoc L ^a   Andela, Valentine ^a   Harhaj, Edward W ^a   Lossos, Izidore S ^a   Harrington Jr , William J ^a,d  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^d UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; INTERFERON REGULATORY FACTOR 4; ONCOPROTEIN; TAX PROTEIN; TRANSCRIPTION FACTOR REL; ZIDOVUDINE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL CLONE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; GENE REARRANGEMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELL LEUKEMIA; T CELL LYMPHOMA; TREATMENT RESPONSE; TUMOR RESISTANCE;

EID: 33947596860     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-07-036368     Document Type: Article

References (73)

1. Gallo RC, Poiesz BJ, Ruscetti FW. Regulation of human T-cell proliferation: T-cell growth factor and isolation of a new class of type-C retroviruses from human T-cells. Haematol Blood Transfus. 1981;26:502-514.
2. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemialymphoma: a report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991;79:428-437.
3. Bazarbachi A, Ghez D, Lepelletier Y, et al. New therapeutic approaches for adult T-cell leukaemia. Lancet Oncol. 2004;5:664-672.
4. Yamada Y, Tomonaga M, Fukuda H, et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol. 2001;113:375-382.
5. Taguchi H, Kinoshita KI, Takatsuki K, et al. An intensive chemotherapy of adult T-cell leukemia/lymphoma: CHOP followed by etoposide, vindesine, ranimustine, and mitoxantrone with granulocyte colony-stimulating factor support. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;12:182-186.
6. Utsunomiya A, Miyazaki Y, Takatsuka Y, et al. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;27:15-20.
7. Nakase K, Hara M, Kozuka T, Tanimoto K, Nawa Y. Bone marrow transplantation from unrelated donors for patients with adult T-cell leukaemia/lymphoma. Bone Marrow Transplant. 2006;37:41-44.
8. Waldmann TA, White JD, Carrasquillo JA, et al. Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood. 1995;86:4063-4075.
9. Waldmann TA. The promiscuous IL-2/IL-15 receptor: a target for immunotherapy of HTLV-1-associated disorders. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13:S179-S185.
10. Gill PS, Harrington W Jr, Kaplan MH, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med. 1995;332:1744-1748.
11. Hermine O, Bouscary D, Gessain A, et al. Treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med. 1995;332:1749-1751.
12. Matutes E, Taylor GP, Cavenagh J, et al. Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients. Br J Haematol. 2001;113:779-784.
13. Hermine O, Allard I, Levy V, et al. A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol J. 2002;3:276-282.
14. Datta A, Bellon M, Sinha-Datta U, et al. Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. Blood. 2006;108:1021-1029
15. Thyrell L, Erickson S, Zhivotovsky B, et al. Mechanisms of interferon-alpha induced apoptosis in malignant cells. Oncogene. 2002;21:1251-1262.
16. Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist. 2001;6:34-55.
17. Pansky A, Hildebrand P, Fasler-Kan E, et al. Defective Jak-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon-alpha. Int J Cancer. 2000;85:720-725.
18. Xu B, Grander D, Sangfelt O, Einhorn S. Primary leukemia cells resistant to alpha-interferon in vitro are defective in the activation of the DNA-binding factor interferon-stimulated gene factor 3. Blood. 1994;84:1942-1949.
19. Sun WH, Pabon C, Alsayed Y, et al. Interferon-alpha resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression. Blood. 1998;91:570-576.
20. Tajima K, Cartier L. Epidemiological features of HTLV-1 and adult T cell leukemia. Intervirology. 1995;38:238-246.
21. Maeda M, Shimizu A, Ikuta K, et al. Origin of human T-lymphotrophic virus I-positive T cell lines in adult T cell leukemia: analysis of T cell receptor gene rearrangement. J Exp Med. 1985;162:2169-2174.
22. Yoshida M. Multiple viral strategies of HTLV-1 for dysregulation of cell growth control. Annu Rev Immunol. 2001;19:475-496.
23. Mori N, Fujii M, Ikeda S, et al. Constitutive activation of NF-κB in primary adult T-cell leukemia cells. Blood. 1999;93:2360-2368.
24. Arima N, Matsushita K, Obata H, et al. NF-κB involvement in the activation of primary adult T-cell leukemia cells and its clinical implications. Exp Hematol. 1999;27:1168-1175.
25. Cahir-McFarland ED, Davidson DM, Schauer SL, Duong J, Kieff E. NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. Proc Natl Acad Sci U S A. 2000;97:6055-6060.
26. Keller SA, Schattner EJ, Cesarman E. Inhibition of NF-κB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood. 2000;96:2537-2542.
27. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001;194:1861-1874.
28. Mori N, Yamada Y, Ikeda S, et al. Bay 11-7082 inhibits transcription factor NF-κB and induces apoptosis of HTLV-1-infected T-cell lines and primary adult T-cell leukemia cells. Blood. 2002;100:1828-1834.
29. Satou Y, Nosaka K, Koya Y, Yasunaga JI, Toyokuni S, Matsuoka M. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. Leukemia. 2004;18:1357-1363.
30. Ohsugi T, Horie R, Kumasaka T, et al. In vivo antitumor activity of the NF-κB inhibitor dehydroxy-methylepoxyquinomicin in a mouse model of adult T-cell leukemia. Carcinogenesis. 2005;26:1382-1388.
31. Lairmore MD, Silverman L, Ratner L. Animal models for human T-lymphotropic virus type 1 (HTLV-1) infection and transformation. Oncogene. 2005;24:6005-6015.
32. Miller JE, Wilson SS, Jaye DL, Kronenberg M. An automated semiquantitative B and T cell clonality assay. Mol Diagn. 1999;4:101-117.
33. van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17:2257-317.
34. Kurokawa M, Ghosh SK, Ramos JC, et al. Zidovudine inhibits NF-κB and induces Epstein-Barr virus gene expression in Burkitt lymphoma. Blood. 2005;106:235-240.
35. Nakanishi C, Toi M. Nuclear factor-κB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer. 2005;5:297-309.
36. Hrdlickova R, Nehyba J, Bose HR Jr. Interferon regulatory factor 4 contributes to transformation of v-Rel-expressing fibroblasts. Mol Cell Biol. 2001;21:6369-6386.
37. Mittrucker HW, Matsuyama T, Grossman A, et al. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science. 1997;275:540-543.
38. Lohoff M, Mittrucker HW, Brustle A, et al. Enhanced TCR-induced apoptosis in interferon regulatory factor 4-deficient CD4(+) Th cells. J Exp Med. 2004;200:247-253.
39. Iida S, Rao PH, Butler M, et al. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet. 1997;17:226-230.
40. Carbone A, Gloghini A, Larocca LM, et al. Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. Blood. 2001;97:744-751.
41. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;1030:275-282.
42. Muris JJ, Meijer CJ, Vos W, et al. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol. 2006;208:714-723.
43. Ito M, Iida S, Inagaki H, et al. MUM1/IRF4 expression is an unfavorable prognostic factor in B-cell chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Jpn J Cancer Res. 2002;93:685-694.
44. Sundram U, Kim Y, Mraz-Gernhard S, Hoppe R, Natkunam Y, Kohler S. Expression of the bcl-6 and MUM1/IRF4 proteins correlate with overall and disease-specific survival in patients with primary cutaneous large B-cell lymphoma: a tissue microarray study. J Cutan Pathol. 2005;32:227-234.
45. Imaizumi Y, Kohno T, Yamada Y, et al. Possible involvement of interferon regulatory factor 4 (IRF4) in a clinical subtype of adult T-cell leukemia. Jpn J Cancer Res. 2001;92:1284-1292.
46. Grumont RJ, Gerondakis S. Rel induces interferon regulatory factor 4 (IRF-4) expression in lymphocytes: modulation of interferon-regulated gene expression by rel/nuclear factor κB. J Exp Med. 2000;191:1281-1292.
47. Yamagata T, Nishida J, Tanaka S, et al. A novel interferon regulatory factor family transcription factor, ICSAT/Pip/LSIRF, that negatively regulates the activity of interferon-regulated genes. Mol Cell Biol. 1996;16:1283-1294.
48. Sharma S, Mamane Y, Grandvaux N, et al. Activation and regulation of interferon regulatory factor 4 in HTLV type 1-infected T lymphocytes. AIDS Res Hum Retroviruses. 2000;16:1613-1622.
49. Mamane Y, Grandvaux N, Hernandez E, et al. Repression of IRF-4 target genes in human T cell leukemia virus-1 infection. Oncogene. 2002;21:6751-6765.
50. Sharma S, Grandvaux N, Mamane Y, et al. Regulation of IFN regulatory factor 4 expression in human T cell leukemia virus-I-transformed T cells. J Immunol. 2002;169:3120-3130.
51. Hisada M, Okayama A, Shioiri S, Spiegelman DL, Stuver SO, Mueller NE. Risk factors for adult Tcell leukemia among carriers of human T-lymphotropic virus type I. Blood. 1998;92:3557-3561.
52. Hermine O, Dombret H, Poupon J, et al. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. Hematol J. 2004;5:130-134.
53. Hatta Y, Koeffler HP. Role of tumor suppressor genes in the development of adult T cell leukemia/lymphoma (ATLL). Leukemia. 2002;16:1069-1085.52.
54. Nakayama K, Kamihira S. Survivin an important determinant for prognosis in adult T-cell leukemia: a novel biomarker in practical hemato-oncology. Leuk Lymphoma. 2002;43:2249-2255.
55. Kamihira S, Yamada Y, Hirakata Y, et al. Aberrant expression of caspase cascade regulatory genes in adult T-cell leukaemia: survivin is an important determinant for prognosis. Br J Haematol. 2001;114:63-69.
56. Hasegawa H, Yamada Y, Harasawa H, et al. Sensitivity of adult T-cell leukaemia lymphoma cells to tumour necrosis factor-related apoptosis-inducing ligand. Br J Haematol. 2005;128:253-265.
57. Ohshima K, Haraoka S, Sugihara M, et al. Amplification and expression of a decoy receptor for fas ligand (DcR3) in virus (EBV or HTLV-1) associated lymphomas. Cancer Lett. 2000;160:89-97.
58. Weih F, Carrasco D, Bravo R. Constitutive and inducible Rel/NF-kappa B activities in mouse thymus and spleen. Oncogene. 1994;9:3289-3297.
59. Carrasco D, Rizzo CA, Dorfman K, et al. The v-rel oncogene promotes malignant T-cell leukemia/lymphoma in transgenic mice. EMBO J. 1996;15:3640-3650.
60. Gilmore TD, Cormier C, Jean-Jacques J, Gapuzan ME. Malignant transformation of primary chicken spleen cells by human transcription factor c-Rel. Oncogene. 2001;20:7098-7103.
61. Rosenwald A, Staudt LM. Gene expression profiling of diffuse large B-cell lymphoma. Leuk Lymphoma. 2003;44(suppl 3):S41-S47.
62. Barth TF, Martin-Subero JI, Joos S, et al. Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma. Blood. 2003;101:3681-3686.
63. Pileri SA, Zinzani PL, Gaidano G, et al. Pathobiology of primary mediastinal B-cell lymphoma. Leuk Lymphoma. 2003;44(suppl):S21-S26.
64. Kontgen F, Grumont RJ, Strasser A, et al. Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. Genes Dev. 1995;9:1965-1977.
65. Maeda M, Arima N, Daitoku Y, et al. Evidence for the interleukin-2 dependent expansion of leukemic cells in adult T cell leukemia. Blood. 1987;70:1407-1411.
66. Dewan MZ, Terashima K, Taruishi M, et al. Rapid tumor formation of human T-cell leukemia virus type 1-infected cell lines in novel NOD-SCID/ γc(null) mice: suppression by an inhibitor against NF-κB. J Virol. 2003;77:5286-5294.
67. Hasegawa H, Sawa H, Lewis MJ, et al. Thymus-derived leukemia-lymphoma in mice transgenic for the Tax gene of human T-lymphotropic virus type I. Nat Med. 2006;12:466-472.
68. Marecki S, Atchison ML, Fenton MJ. Differential expression and distinct functions of IFN regulatory factor 4 and IFN consensus sequence binding protein in macrophages. J Immunol. 1999;163:2713-2722.
69. Falini B, Fizzotti M, Pucciarini A, et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood. 2000;95:2084-2092.
70. Pernis AB. The role of IRF-4 in B and T cell activation and differentiation. J Interferon Cytokine Res. 2002;22:111-120.
71. Negishi H, Ohba Y, Yanai H, et al. Negative regulation of Toll-like-receptor signaling by IRF-4. Proc Natl Acad Sci U S A. 2005;102:15989-15994.
72. Zong WX, Edelstein LC, Chen C, Bash J, Gelinas C. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-κB that blocks TNFα-induced apoptosis. Genes Dev. 1999;13:382-387.
73. Leclercq I, Mortreux F, Morschhauser F, et al. Semiquantitative analysis of residual disease in patients treated for adult T-cell leukaemia/lymphoma (ATLL). Br J Haematol. 1999;105:743-751.